Extended-spectrum Beta-lactamases and AmpC Enzymes of Pseudomonas aeruginosa:Their Detection and Resistance Analysis
- VernacularTitle:铜绿假单胞菌超广谱?-内酰胺酶、AmpC酶的检测及耐药性分析
- Author:
Jun MENG
;
Sufang GUO
;
Junli ZHANG
- Publication Type:Journal Article
- Keywords:
Pseudomonas aeruginosa;
Extended-spectrum ?-lactamases;
AmpC enzymes;
Drug resistance
- From:
Chinese Journal of Nosocomiology
2009;0(18):-
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To investigate the prevalence of strains producing extended-spectrum ?-lactamases (ESBLs) and AmpC ?-lactamases in Pseudomonas aeruginosa,and to supply the laboratory evidence for antibiotic rational application in clinic. METHODS Totally 105 clinical isolates of P. aeruginosa were identified with VITEK-32. Drug sensitivities were determined by Kirby-Bauer methods. ESBLs were detected by double-disc synergy test,and cefoxitin three dimensional test was applied to filter AmpC positive strains. RESULTS Among 105 strains of P. aeruginosa,28 strains (26.7%) were AmpC enzymes positive,20 strains (19.0%) were ESBLs positive,and 5 strains(4.8%)were AmpC+ESBLs positive. The detective rate of producing AmpC ?-lactamases strains was higher than that of producing ESBLs strains. There was significant difference between them. CONCLUSIONS ESBLs and AmpC ?-lactamases are two main enzyme types conferring resistance to ?-lactam antibiotics in clinical isolates of P. aeruginosa. Imipenem can be the first choice for treating infections caused by P. aeruginosa producing ESBLs or AmpC ?-lactamases.
